ACHN Soars On PNH Data, ACAD Abuzz, ALDR On Track, Zealand To Debut On Nasdaq

Today's Daily Dose brings you news about Achillion's phase II trial results of ACH-4471 in paroxysmal nocturnal hemoglobinuria; ACADIA's improving financials; Alder's near-term catalysts; Navidea's progress in its pipeline and Theravence's anticipated milestones.

from RTT - Biotech http://ift.tt/2wHc5ii
via IFTTT